BIOMAT Database Logo BIOMAT Database Logo

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). 2001

S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.

L: -FMAU [1-(2-fluoro-5-methyl-beta,L-arabinofuranosyl) uracil] has been shown to be an effective inhibitor of hepatitis B virus (HBV) and duck hepatitis B virus replication in cell culture and duck hepatitis B virus replication in acutely infected Peking ducks. The woodchuck hepatitis virus (WHV) and its natural host, the Eastern woodchuck (Marmota monax), have been established as a predictive model for the evaluation of antiviral therapies against chronic HBV infection. In this report, the antiviral activity of l-FMAU against WHV replication in chronically infected woodchucks is described. Four weeks of once-daily oral administration of L-FMAU significantly reduced viremia, antigenemia, intrahepatic WHV replication, and intrahepatic expression of woodchuck hepatitis virus core antigen (WHcAg) in a dose-dependent manner. At the highest dose administered (10 mg/kg/d), significant reductions of intrahepatic WHV RNA and covalently closed circular (ccc)WHV-DNA levels also were observed. The reduction in viremia was remarkably rapid at the higher doses of L-FMAU, with greater than 1,000-fold reductions in WHV-DNA serum levels observed after as little as 2 to 3 days of therapy. Following the withdrawal of therapy, a dose-related delay in viremia rebound was observed. At the highest doses used, viremia remained significantly suppressed in at least one half of the treated animals for 10 to 12 weeks' posttreatment. No evidence of drug-related toxicity was observed in the treated animals. L-FMAU is an exceptionally potent antihepadnaviral agent in vitro and in vivo, and is a suitable candidate for antiviral therapy of chronic HBV infection.

UI MeSH Term Description Entries
D008392 Marmota A genus of Sciuridae consisting of 14 species. They are shortlegged, burrowing rodents which hibernate in winter. Woodchucks,Marmots,Marmot,Marmotas,Woodchuck
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D004270 DNA, Circular Any of the covalently closed DNA molecules found in bacteria, many viruses, mitochondria, plastids, and plasmids. Small, polydisperse circular DNA's have also been observed in a number of eukaryotic organisms and are suggested to have homology with chromosomal DNA and the capacity to be inserted into, and excised from, chromosomal DNA. It is a fragment of DNA formed by a process of looping out and deletion, containing a constant region of the mu heavy chain and the 3'-part of the mu switch region. Circular DNA is a normal product of rearrangement among gene segments encoding the variable regions of immunoglobulin light and heavy chains, as well as the T-cell receptor. (Riger et al., Glossary of Genetics, 5th ed & Segen, Dictionary of Modern Medicine, 1992) Circular DNA,Circular DNAs,DNAs, Circular
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001086 Arabinofuranosyluracil A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE. Ara-U,Arabinosyluracil,Arauridine,Sponguridine,Uracil Arabinofuranoside,Uracil Arabinoside,1-beta-D-Arabinofuranosyl Uracil,NSC 68928,1 beta D Arabinofuranosyl Uracil,Ara U,Arabinofuranoside, Uracil,Arabinoside, Uracil,Uracil, 1-beta-D-Arabinofuranosyl

Related Publications

S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks.
October 1997, Antimicrobial agents and chemotherapy,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
April 2001, Antimicrobial agents and chemotherapy,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Nitrite and nitrosamine synthesis by hepatocytes isolated from normal woodchucks (Marmota monax) and woodchucks chronically infected with woodchuck hepatitis virus.
August 1992, Cancer research,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
February 1998, Antimicrobial agents and chemotherapy,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Hepatic lesions in woodchucks (Marmota monax) seronegative for woodchuck hepatitis virus.
April 1991, Journal of wildlife diseases,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats.
April 1996, Biopharmaceutics & drug disposition,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus.
September 2004, Virology,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Serologic survey of woodchuck hepatitis virus in North Carolina woodchucks (Marmota monax).
June 2008, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.
June 2002, Journal of virology,
S F Peek, and P J Cote, and J R Jacob, and I A Toshkov, and W E Hornbuckle, and B H Baldwin, and F V Wells, and C K Chu, and J L Gerin, and B C Tennant, and B E Korba
Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax).
April 1996, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!